Tang Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Tang Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-90,215	Closed	-$8.4M	–	5
2017 Q3	$8.4M	Hold	90,215	–	–	2.56%	4
2017 Q2	$8.19M	Hold	90,215	–	–	2.91%	4
2017 Q1	$7.92M	Hold	90,215	–	–	2.86%	4
2016 Q4	$7.47M	Hold	90,215	–	–	3.99%	5
2016 Q3	$8.35M	Hold	90,215	–	–	3.46%	5
2016 Q2	$7.02M	Hold	90,215	–	–	3.13%	5
2016 Q1	$7.44M	Hold	90,215	–	–	3.39%	4
2015 Q4	$9.45M	Sell	90,215 -92,085	-51%	-$9.62M	3.75%	4
2015 Q3	$19.2M	Hold	182,300	–	–	7.08%	4
2015 Q2	$24.9M	Hold	182,300	–	–	7.57%	5
2015 Q1	$22.7M	Hold	182,300	–	–	12.08%	4
2014 Q4	$16.5M	Hold	182,300	–	–	9.04%	5
2014 Q3	$13.2M	Hold	182,300	–	–	6.82%	6
2014 Q2	$11.3M	Hold	182,300	–	–	5.25%	6
2014 Q1	$12.4M	Hold	182,300	–	–	6.03%	6
2013 Q4	$12.8M	Hold	182,300	–	–	8.97%	5
2013 Q3	$13.2M	Hold	182,300	–	–	6.52%	8
2013 Q2	$10.2M	Buy	+182,300	New	+$11.4M	4%	10

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tang Capital Management's BMRN Position: Q4 2017 in Review

Tang Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 90,215 shares — an estimated $8.4M sold.

Tang Capital Management first reported a position in BMRN in Q2 2013 and held it in 18 quarters. The position peaked at $24.9M in Q2 2015. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

Tang Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Tang Capital Management sold 90,215 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $8.4M.
Tang Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 18 quarters.
Tang Capital Management's BioMarin Pharmaceuticals position peaked at $24.9M in Q2 2015.
438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Tang Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.